BACKGROUND: Markers of an acute phase reaction, such as C-reactive protein (CRP) or tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, are predictive for cardiovascular morbidity and mortality in normal subjects and in chronic renal failure patients. In this study, we aimed to investigate serum TNF-alpha, IL-6, IL-10 and CRP levels in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients. MATERIALS AND METHODS: Serum levels of TNF-alpha, IL-6, IL-10 and CRP levels were measured in 30 patients who were just diagnosed with end-stage renal failure and treated, with 16 CAPD (nine female, seven male) and 14 HD (eight female, six male) patients, before CAPD or HD treatment and after 3 months from the beginning of CAPD or HD in patients with no clinical signs of infection. The control groups were 20 healthy persons of similar age and sex. Serum levels of TNF-alpha, IL-6, IL-10 and CRP were measured by enzyme-linked immunosorbent assay in stable CAPD and HD patients and in healthy persons. RESULTS: The mean serum levels of TNF-alpha, IL-6, IL-10 and CRP showed no significant differences between the CAPD and HD patients for the beginning values and the third month of treatment. However, serum TNF-alpha, IL-6, IL-10 and CRP levels were higher than the control group in the CAPD and HD patients regarding the beginning values and the third month of treatment (p < 0.001). CONCLUSIONS: CAPD and HD of the renal replacement therapy have no effects on serum CRP and cytokines.
BACKGROUND: Markers of an acute phase reaction, such as C-reactive protein (CRP) or tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, are predictive for cardiovascular morbidity and mortality in normal subjects and in chronic renal failurepatients. In this study, we aimed to investigate serum TNF-alpha, IL-6, IL-10 and CRP levels in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients. MATERIALS AND METHODS: Serum levels of TNF-alpha, IL-6, IL-10 and CRP levels were measured in 30 patients who were just diagnosed with end-stage renal failure and treated, with 16 CAPD (nine female, seven male) and 14 HD (eight female, six male) patients, before CAPD or HD treatment and after 3 months from the beginning of CAPD or HD in patients with no clinical signs of infection. The control groups were 20 healthy persons of similar age and sex. Serum levels of TNF-alpha, IL-6, IL-10 and CRP were measured by enzyme-linked immunosorbent assay in stable CAPD and HDpatients and in healthy persons. RESULTS: The mean serum levels of TNF-alpha, IL-6, IL-10 and CRP showed no significant differences between the CAPD and HDpatients for the beginning values and the third month of treatment. However, serum TNF-alpha, IL-6, IL-10 and CRP levels were higher than the control group in the CAPD and HDpatients regarding the beginning values and the third month of treatment (p < 0.001). CONCLUSIONS: CAPD and HD of the renal replacement therapy have no effects on serum CRP and cytokines.
Authors: C H Bolton; L G Downs; J G Victory; J F Dwight; C R Tomson; M I Mackness; J H Pinkney Journal: Nephrol Dial Transplant Date: 2001-06 Impact factor: 5.992
Authors: Tomasz Stompór; Mieczyslsław Pasowicz; Władysław Sulłowicz; Aldona Dembińska-Kieć; Katarzyna Janda; Katarzyna Wójcik; Wiesława Tracz; Anna Zdzienicka; Piotr Klimeczek; Eve Janusz-Grzybowska Journal: Am J Kidney Dis Date: 2003-01 Impact factor: 8.860
Authors: Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco Journal: Cardiorenal Med Date: 2013-04 Impact factor: 2.041
Authors: Andrea Schlotterer; Friederike Pfisterer; Georgi Kukudov; Britta Heckmann; Daniel Henriquez; Christian Morath; Bernhard K Krämer; Hans-Peter Hammes; Vedat Schwenger; Michael Morcos Journal: Biomed Rep Date: 2018-04-03
Authors: Dorota Kamińska; Katarzyna Kościelska-Kasprzak; Paweł Chudoba; Oktawia Mazanowska; Mirosław Banasik; Marcelina Żabinska; Maria Boratyńska; Agnieszka Lepiesza; Krzysztof Korta; Agnieszka Gomółkiewicz; Piotr Dzięgiel; Marian Klinger Journal: Biomed Res Int Date: 2015-07-08 Impact factor: 3.411